Clinical Trials Logo

Joint Diseases clinical trials

View clinical trials related to Joint Diseases.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT06044974 Enrolling by invitation - Clinical trials for Temporomandibular Joint Disorders

Nd-YAG Laser Versus Epidermal Growth Factor in the Treatment of Myogenic Tempromandibular Disorder (Randomized Clinical Trial)

Start date: January 21, 2023
Phase: Phase 4
Study type: Interventional

A clinical trial comparing the potential effect of 2 different modalities (Nd-YAG Laser Versus Epidermal growth factor injection) on pain reduction in patients suffering from myogenic tempromandibular disorder.

NCT ID: NCT05980234 Enrolling by invitation - Osteoarthritis Clinical Trials

MDR - Longevity IT Oblique and Offset Liners

Start date: August 30, 2023
Phase:
Study type: Observational

The objective of this retrospective enrollment/prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Longevity IT Oblique and Offset liners when used for primary or revision total hip arthroplasty (implants and instrumentation) at a minimum of 10-year follow-up.

NCT ID: NCT05916092 Enrolling by invitation - Clinical trials for Sacroiliac Joint Dysfunction

Post-Market Clinical Study on a Modular SI Joint Fusion System

SPARTAN
Start date: October 19, 2023
Phase:
Study type: Observational

A prospective study on the use of the TransLoc 3D SI Joint Fusion System for patients with sacroiliac joint disruptions or degenerative sacroiliitis.

NCT ID: NCT05817162 Enrolling by invitation - Clinical trials for Temporomandibular Joint Disorders

Temporomandibular Joint Arthrocentesis With Infiltration of PRP + Ropivacaine Versus PRP

Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

The infiltration of Platelet Rich Plasma (PRP) at the end of Temporomandibular Joint (TMJ) arthrocentesis is already an established procedure in the treatment of Temporomandibular Disorders (TMD). Arthrocentesis is a minimally invasive surgical procedure, which aims to eliminate the inflammatory mediators from the inside of the TMJ. PRP is an autologous concentrate of platelets and growth factors, derived from centrifugated blood. Several studies have described the benefits of PRP: it enhances wound healing because of the presence of cytokines and growth factors, and is also stimulates chondrocytes to biosynthesis of collagen. Ropivacaine is a local anesthetic that has been synthesized for use in infiltration anesthesia and to produce both peripheral and central block. Unlike one of its analogues, Bupivacaine, Ropivacaine anesthetize the sensory fibers without affecting the motor ones. The main goal of this investigation is to test the benefits of adding Ropivacaine to the infiltration of PRP in patients submitted to TMJ arthrocentesis.

NCT ID: NCT05712850 Enrolling by invitation - Clinical trials for Sacroiliac Joint Dysfunction

Clinical Outcome and Fusion Results Using the SiJoin® Transfixing Sacroiliac Fusion Device

Start date: January 19, 2023
Phase:
Study type: Observational

The purpose of this clinical study is to evaluate fusion of the SI joint(s) and any reduction in VAS pain scores in a prospective cohort of patients utilizing the SiJoin® Transfixing Sacroiliac Fusion Device in patients that received sacroiliac fusion, without ancillary stabilization devices.

NCT ID: NCT05548972 Enrolling by invitation - Clinical trials for Rheumatoid Arthritis

G7 Dual Mobility With Vivacit-E or Longevity PMCF

Start date: March 20, 2023
Phase: N/A
Study type: Interventional

This study is a global, multi-center, prospective, non-controlled, non-randomized, post-market clinical follow-up study. The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Dual Mobility Acetabular System when used with the Vivacit-E or Longevity polyethylene hip bearing and instrumentation in primary total and revision (total) hip arthroplasty

NCT ID: NCT04816773 Enrolling by invitation - Osteoarthritis Clinical Trials

Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert

Start date: January 27, 2022
Phase:
Study type: Observational

MicroPort Orthopedics Inc. (MPO) plans to market the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert globally, including in the European Union (EU). MPO is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and effectiveness of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur. These components are used along with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert components that is marketed in the European Union (EU). This type of data collection is required by regulatory authorities for all TKA devices that do not have medium to long-term clinical evidence available.

NCT ID: NCT04618237 Enrolling by invitation - Hemophilia Clinical Trials

Observational Study of Long-Term Joint Health Outcome in Hemophilia Patient

Start date: July 20, 2020
Phase:
Study type: Observational

Patients with severe hemophilia A can experience repeated bleeding into the same joint (ie, a target joint; most frequently in the ankle, knee, and elbow), which can contribute to hemophilic arthropathy and, over time, ultimately result in chronic pain, functional limitations, deformities, reduced joint of motion and decreased quality of life. Early use of prophylaxis is recommended following diagnosis of severe hemophilia A to maintain joint health and prevent joint destruction. Eloctate is produced using a human cell line and an addition of an Fc fusion protein to recombinant FVIII (rFVIIIFc) with prolonged half-life and was launched in Taiwan from Nov. 2018. The pivotal studies of rFVIIIFc show that patients maintained a low bleeding rate, with most experiencing a median annualized bleeding rate (ABR) of 0 and 97% of target joints were resolved across adult, adolescent, and pediatric subjects during 4 years of prophylaxis rFVIIIFc treatment. However, in Taiwan we are still lacking the real world treatment outcome data on rFVIIIFc, especially for the joint health evidence in Asian Hemophilia A patients. Therefore the objective of this study is to evaluate the effectiveness of rFVIIIFc treatment on joint health over a long observational period of 36 month focused on physical and functional changes in hemophilia A patients.

NCT ID: NCT04147559 Enrolling by invitation - Joint Diseases Clinical Trials

Post Market Clinical Follow-Up Study for PROFEMUR® Preserve Classic Femoral Stem

Start date: October 21, 2020
Phase:
Study type: Observational

Sponsor is conducting this post market clinical study to evaluate the safety and effectiveness of its PROFEMUR® Preserve Classic Femoral Stem. This type of study is required by regulatory authorities for all devices that have been approved in Europe (EU) to evaluate the medium and long-term clinical evidence. This study has been designed in accordance with MEDDEV2.12/2 (European Medical Device Vigilance System) rev2 and ISO (International Organization of Standardization) 14155:2011 guidelines.

NCT ID: NCT04064008 Enrolling by invitation - Joint Disease Clinical Trials

Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Z Revision Femoral Stems

Start date: April 4, 2019
Phase:
Study type: Observational

Single center, prospective follow-up of previously implanted subjects